FNYS
ORKA

First New York Securities’s Oruka Therapeutics ORKA Stock Holding History

First New York Securities’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5
Closed -$14K – 490
2013
Q4 		$14K Buy
+5
New +$11.5K 0.01% 237

Other funds holding ORKA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
AL
Airain Ltd St. Peter Port, Guernsey $2.26B AUM 12.43% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

First New York Securities's ORKA Position: Q1 2014 in Review

First New York Securities sold out of Oruka Therapeutics (ORKA) in Q1 2014, closing a stake of 5 shares — an estimated $14K sold.

First New York Securities first reported a position in ORKA in Q4 2013 and held it in 1 quarter. The position peaked at $14K in Q4 2013. 11 funds tracked by Wall St. Rank hold ORKA as of Q1 2014.

  • First New York Securities reported no remaining Oruka Therapeutics position as of Q1 2014 after selling out during the quarter.
  • First New York Securities sold 5 Oruka Therapeutics shares in Q1 2014, an estimated $14K.
  • First New York Securities first reported a position in Oruka Therapeutics in Q4 2013 and held it in 1 quarter.
  • First New York Securities's Oruka Therapeutics position peaked at $14K in Q4 2013.
  • 11 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2014.

Based on First New York Securities's 13F filing for Q1 2014, filed 15 May 2014.